Immediate outcomes of eptifibatide therapy during intracoronary stent implantation

Document Type : Original Article


1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Interventional Cardiologist, Chamran Hospital, Isfahan University of Medical Sciences, Isfahan, Iran


Background: The objective of the present study was to assess the major immediate outcomes of eptifibatide therapy during intracoronary stent implantation.
Materials and Methods: In an interventional study, patients undergoing percutaneous coronary intervention (PCI) were randomized into either the eptifibatide (n = 100) or the control (n = 107) group. In each group, demographic and clinical characteristics such as cardiac death, stent thrombosis (ST), myocardial infarction (MI), rates of target lesion and vessel revascularization, cerebral vascular accident (CVA), and emergency coronary artery bypass grafting (CABG) were recorded.
Results: The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P > 0.05 considered significant for all comparisons.
Conclusion: There were no statistical differences between the clinical outcomes of groups administered with single-dose intracoronary eptifibatide and control groups among patients undergoing PCI during stent implantation.


Skoog M, Grevstad B, Wetterslev J, Hróbjartsson A, Gluud C. Antibiotics for secondary prevention of coronary heart disease. The Cochrane Library 2013.  Back to cited text no. 1
Htay T, Liu MW. Drug-eluting stent: A review and update. Vasc Health Risk Manag 2005;1:263-76.  Back to cited text no. 2
Raveendran G, Ting HH, Best PJ, Holmes DR Jr, Lennon RJ, Singh M, et al. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. Mayo Clin Proc 2007;82:196-202.  Back to cited text no. 3
Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.  Back to cited text no. 4
Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-65.  Back to cited text no. 5
Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-35.  Back to cited text no. 6
Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999;281:1407-14.  Back to cited text no. 7
Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, et al.; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008;51:529-35.  Back to cited text no. 8
Horne BD, Knight S, May HT. Panoptic total cardiovascular risk prediction using all predictors versus optimized risk assessment using variable subsets. Future Cardiol 2012;8:765-78.  Back to cited text no. 9
Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 2000;101:751-7.  Back to cited text no. 10
ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-44.  Back to cited text no. 11
Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005;26:1971-7.  Back to cited text no. 12
Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, et al. ESPRIT Investigators. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv 2007;70:43-50.  Back to cited text no. 13
Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv 2009;73:214-21.  Back to cited text no. 14
O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial) Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA 2001;285:2468-73.  Back to cited text no. 15
Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: The Intracoronary Eptifibatide (ICE) Trial. Circulation 2010;121:784-91.  Back to cited text no. 16
Midei MG, Coombs VJ, Lowry DR, Drossner MN, Prewitt KC, Wang JC, et al. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions. Cardiology 2006;107:172-7.  Back to cited text no. 17
Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004;4:26.  Back to cited text no. 18
Biondi-Zoccai GG, Valgimigli M, Sheiban I, Margheri M, Marzocchi A, Prati F, et al. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: Design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. J Cardiovasc Med (Hagerstown) 2008;9:957-62.  Back to cited text no. 19
Biondi-Zoccai GG, Sangiorgi GM, Antoniucci D, Grube E, Di Mario C, Reimers B, et al. Taxus in Real-life Usage Evalutaion Study. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: Design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in real-life usage evaluation (TRUE) study. Int J Cardiol 2007;117:349-54.  Back to cited text no. 20
Aldea GS. Use of heparin-bonded cardiopulmonary bypass circuits with alternatives to standard anticoagulation. Advanced Therapy in Cardiac Surgery 2003;103:46.  Back to cited text no. 21
Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6.  Back to cited text no. 22
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.  Back to cited text no. 23
O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, et al. ESPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287:618-21.  Back to cited text no. 24
Granada JF, Kleiman NS. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting. Am J Cardiovasc Drugs 2004;4:31-41.  Back to cited text no. 25
O'Shea JC, Tcheng JE. Eptifibatide: A potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. Expert Opin Pharmacother 2002;3:1199-210.  Back to cited text no. 26